Fresenius Medical Care (NYSE:FMS) Upgraded at StockNews.com

StockNews.com upgraded shares of Fresenius Medical Care (NYSE:FMS) from a hold rating to a strong-buy rating in a research report report published on Wednesday.

A number of other brokerages also recently commented on FMS. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Berenberg Bank initiated coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target for the company. Finally, Truist Financial upped their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th.

Fresenius Medical Care Price Performance

Shares of FMS opened at $24.54 on Wednesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The company has a 50 day moving average price of $23.29 and a 200-day moving average price of $21.30. Fresenius Medical Care has a fifty-two week low of $17.93 and a fifty-two week high of $25.25. The stock has a market capitalization of $14.40 billion, a PE ratio of 20.28, a PEG ratio of 0.82 and a beta of 0.93.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. The company had revenue of $5.23 billion during the quarter, compared to the consensus estimate of $5.36 billion. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. During the same quarter in the previous year, the firm posted $0.31 earnings per share. Equities analysts predict that Fresenius Medical Care will post 1.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care

Several hedge funds have recently added to or reduced their stakes in FMS. Smartleaf Asset Management LLC lifted its holdings in shares of Fresenius Medical Care by 192.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after buying an additional 806 shares during the period. Allworth Financial LP lifted its holdings in Fresenius Medical Care by 53.1% in the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after acquiring an additional 581 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Fresenius Medical Care in the 3rd quarter worth approximately $38,000. GAMMA Investing LLC grew its stake in shares of Fresenius Medical Care by 50.4% during the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after purchasing an additional 1,675 shares during the period. Finally, ORG Wealth Partners LLC purchased a new position in shares of Fresenius Medical Care during the 3rd quarter valued at approximately $112,000. 8.37% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.